Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05144997 · ClinicalTrials.gov registry record · Phase 4

Lorlatinib Continuation Study

A Phase 4 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Pfizer.

Active
Registry status
Phase 4
Development phase
76
Enrollment target
20
Study locations

NCT05144997 is a Phase 4 study of Non-Small Cell Lung Cancer and NSCLC that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 76 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05144997, a Phase 4 study of Non-Small Cell Lung Cancer and NSCLC, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
76 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention

Conditions Studied

Non-Small Cell Lung Cancer NSCLC

Interventions

  • DRUG Lorlatinib

Study Locations (20)

Zhejiang

  • The First Affiliated Hospital Zhejiang University School of Medicine - Hangzhou
  • Zhejiang Cancer Hospital - Hangzhou
  • The Second Affiliated Hospital of Zhejiang University College of Medicine - Hangzhou

Other

  • Fudan University Shanghai Cancer Center - Shanghai
  • CHU de Rennes - Hôpital Pontchaillou - Rennes
  • Institut Gustave Roussy - Villejuif

Beijing Municipality

  • Beijing Chest Hospital, Capital Medical University - Beijing
  • Beijing Cancer Hospital - Beijing

Jilin

  • Jilin Cancer Hospital - Changchun
  • The first hospital of jilin university - Changchun

California

  • Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine

Anhui

  • The First affiliated Hospital of Anhui Medical University - Hefei

Fujian

  • Fujian Cancer Hospital - Fuzhou

Guangdong

  • Guangdong Provincial People's Hospital - Guangzhou

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2021-12-28
Est. Completion 2026-12-28
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05144997

The ClinicalTrials.gov registry entry for NCT05144997 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lorlatinib is the first listed.

NCT05144997 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Zhejiang, Other, Beijing Municipality.

Frequently Asked Questions

What is clinical trial NCT05144997 about?

NCT05144997 is a clinical study titled "Lorlatinib Continuation Study". The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit...

What is the current status of trial NCT05144997?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2021-12-28. Estimated completion is 2026-12-28.

What conditions does trial NCT05144997 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC.

What interventions are being tested in trial NCT05144997?

The interventions under investigation include: Lorlatinib (DRUG).

Who is sponsoring clinical trial NCT05144997?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05144997 being conducted?

This trial has 20 study locations across California, Anhui, Beijing Municipality, Fujian, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

NSCLC

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.